XWPharma

Neuroscience biotech developing novel therapeutics for sleep, neuropsych, and other underserved CNS disorders.

General Information
Company Name
XWPharma
Founded Year
2014
Location (Offices)
United States +1
Founders / Decision Makers
Number of Employees
16
Industries
Biotechnology, Health Care, Pharmaceutical
Funding Stage
Series C
Social Media

XWPharma - Company Profile

XWPharma is a biotech company with a vision to develop groundbreaking therapeutics for a range of underserved CNS disorders. Established in 2014, the company focuses on the development of novel small molecule drug candidates that target neurological and neuropsychiatric disorders and has a global presence. With a commitment to neuroscience and biotechnology, XWPharma is dedicated to addressing unmet medical needs in the field of sleep, neuropsychiatric, and other CNS disorders. The company's pipeline comprises internally discovered drug candidates that show promise in addressing critical neurological and neuropsychiatric conditions. XWPharma's innovative approach and focus on areas that are currently underserved in the field of central nervous system therapeutics positions it as a noteworthy player in the industry. With a track record of pioneering research and development, XWPharma is poised to make a significant impact on the treatment of these complex disorders, potentially transforming patient care and outcomes. As of the latest available information, XWPharma has not disclosed its last investment round or associated investors. This indicates a potential opportunity for venture capital firms seeking to participate in the growth and development of a pioneering biotech company with a focus on neurological and neuropsychiatric therapeutics. With a headquarters in the United States, XWPharma's global reach and strategic focus make it an intriguing prospect for investors looking to contribute to the advancement of treatment options for CNS disorders.

Taxonomy: neuroscience, biotech, CNS disorders, sleep, neuropsychiatric disorders, narcolepsy, Parkinson's disease, depression, neurological disorders, neurodegeneration, small molecule drugs, novel therapeutics, drug development, Bay Area, global biotech

Funding Rounds & Investors of XWPharma (3)

View All
Funding Stage Amount No. Investors Investors Date
Series C $40.00M 7 Orient Hontai Capital, Johnson & Johnson Robotics and Digital Solutions 18 Sep 2020
Series B $17.50M 3 20 Sep 2017
Series A Unknown - 01 Sep 2014

Latest News of XWPharma

View All

No recent news or press coverage available for XWPharma.

Similar Companies to XWPharma

View All
Hemab Therapeutics - Similar company to XWPharma
Hemab Therapeutics The next generation of therapeutics for bleeding and thrombotic disorders
Zhongze Therapeutics - Similar company to XWPharma
Zhongze Therapeutics Pioneering advances in psychiatric and neurological therapies from discovery to commercialization.
Prilenia - Similar company to XWPharma
Prilenia Dedicated to developing new treatments for neurodegenerative diseases and neurodevelopmental disorders.
AtmosR - Similar company to XWPharma
AtmosR Pioneering treatments to restore autonomous breathing and safety for those with rare central nervous system disorders.
GliaCure - Similar company to XWPharma
GliaCure Pioneering advancements in neurotherapies by harnessing the power of glial cells.